首页 /研究 /Long-Term Efficacy of Risk-Directed, De-Escalated Post-Operative Adjuvant Therapy for Surgically Resected Locally Advanced, Human Papillomavirus-Positive Oropharynx Squamous-Cell Carcinoma (HPV+ OPSCC): A Non-Randomized, Multi-Arm Phase 2 Trial
SURGICAL

Long-Term Efficacy of Risk-Directed, De-Escalated Post-Operative Adjuvant Therapy for Surgically Resected Locally Advanced, Human Papillomavirus-Positive Oropharynx Squamous-Cell Carcinoma (HPV+ OPSCC): A Non-Randomized, Multi-Arm Phase 2 Trial

Wade L. Thorstad, Ryan S. Jackson, Peter Oppelt, Patrik Pipkorn, Jason T. Rich, Jessica Ley, Brianne Thomeczek, Jingxia Liu, José P. Zevallos, S. Puram, D. Adkins

发表年份
2024
引用次数
5

关键词

MedicineHuman papillomavirusOncologyAdjuvantRandomized controlled trialBasal cellInternal medicineAdjuvant therapySurgeryCancer

相关论文

查看 SURGICAL 分类全部论文